Insider · CIK 0001599941

Main David

Reports to the SEC for 1 company · VANCOUVER, A1

sec.gov

Transactions

Companies

Filings

CIK

0001599941

Forms 4 and 5

Insider transactions

19 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2018-08-07	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+415K sh	—	—	415,000
2018-03-09	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+225K sh	—	—	225,000
2017-06-05	NGNENeurogene Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+3,625 sh	$9.60	+$34.8K	75,155
2017-06-05	NGNENeurogene Inc.S Sale	Director, President and CEO	SSale	−3,625 sh	$13.16	−$47.7K	71,530
2017-06-05	NGNENeurogene Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−3,625 sh	—	—	0
2017-06-02	NGNENeurogene Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+6,000 sh	$9.60	+$57.6K	77,530
2017-06-02	NGNENeurogene Inc.S Sale	Director, President and CEO	SSale	−6,000 sh	$13.59	−$81.6K	71,530
2017-06-02	NGNENeurogene Inc. · Stock Option (Right to Buy(M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−6,000 sh	—	—	3,625
2017-06-01	NGNENeurogene Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+6,000 sh	$9.60	+$57.6K	77,530
2017-06-01	NGNENeurogene Inc.S Sale	Director, President and CEO	SSale	−6,000 sh	$13.00	−$78K	71,530
2017-06-01	NGNENeurogene Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−6,000 sh	—	—	9,625
2017-03-08	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+185K sh	—	—	185,000
2016-03-10	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+120K sh	—	—	120,000
2015-03-12	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+65K sh	—	—	65,000
2014-03-12	NGNENeurogene Inc.D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−9,459 sh	$11.00	−$104K	71,530
2014-03-12	NGNENeurogene Inc.C Conversion	Director, President and CEO	CConversion	−71.5K sh	—	—	0
2014-03-12	NGNENeurogene Inc.C Conversion	Director, President and CEO	CConversion	+71.5K sh	—	—	71,530
2014-03-12	NGNENeurogene Inc. · Common Exchangeable SharesD Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−9,459 sh	$11.00	−$104K	0
2014-03-12	NGNENeurogene Inc. · Common Exchangeable SharesC Conversion	Director, President and CEO	CConversion	−71.5K sh	—	—	0

Recent filings

Accepted (ET)
Aug 94
Main David0001209191-18-046098
SEC(opens sec.gov)
Mar 134
Main David0001209191-18-019259
SEC(opens sec.gov)
Jun 54
AQUINOX PHARMACEUTICALS, INC0001209191-17-037966
SEC(opens sec.gov)
Mar 104
AQUINOX PHARMACEUTICALS, INC0001209191-17-020011
SEC(opens sec.gov)
Mar 144
AQUINOX PHARMACEUTICALS, INC0001209191-16-108179
SEC(opens sec.gov)
Mar 164
AQUINOX PHARMACEUTICALS, INC0001209191-15-026541
SEC(opens sec.gov)
Mar 144
AQUINOX PHARMACEUTICALS, INC0001209191-14-020599
SEC(opens sec.gov)

Companies

Neurogene Inc.Director, President and CEONGNE

Address

C/O AQUINOX PHARMACEUTICALS INC. 40 - 887 GREAT NORTHERN WAY

VANCOUVER, A1, V5T 4T5